摘要:
The present disclosure relates to antibody drug conjugates (ADC's) with auristatin E that binds to 191P4D12 protein and variants thereof. 191P4D12 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in some cancers. The ADC's of provide a therapeutic composition for the treatment of cancer.
摘要:
A novel gene (designated 213P1F11) and its encoded protein, and variants thereof, are described wherein 213P1F11 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 213P1F11 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 213P1F11 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be sued to elicit a humoral or cellular immune response; antibodies or T cells reactive with 213P1F11 can be used in active or passive immunization.
摘要:
The present invention provides antibody drug conjugates or antigen binding fragment thereof that bind to 161P2F10B protein, wherein the antibody or antigen binding fragment thereof is conjugated to one or more units of monomethyl auristatin F (MMAF), each unit being conjugated via a linker. Provided are also antibody drug conjugates for use as a medicament, and pharmaceutical compositions that comprise the antibody drug conjugates in a human unit dose form. Further provided are antibody drug conjugates or the pharmaceutical compositions of the invention for use in treating cancer/tumor or inhibiting cancer/tumor growth in a subject.
摘要:
The present invention provides nucleotides encoding an anti-191P4D12 antibody or antigen binding fragment thereof, vectors comprising the nucleotides, and cells comprising the vectors. The invention further provides methods of producing the antibodies of the invention and its fragments as well as antibody-drug conjugates using the cells of the invention.